drugset / Trial / NCT03224260

To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

NCT03224260

Phase 1 Completed 33 enrolled Bristol-Myers Squibb
RandomizedSequentialQuadruple-blindOther

Summary

Access the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy Japanese participants after multiple doses are administered.

Timeline

Start
2017-06-28
Primary completion
2017-11-07
Completion
2017-11-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Milvexian Small molecule 50 mg Oral
Subject Milvexian Small molecule 200 mg Oral
Subject Milvexian Small molecule 500 mg Oral

Indications